CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 201 enrolled
Drug / intervention
Gemcitabinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03724994
NCT03724994N/ACompleted
CompareCT.gov

Chemotherapy, Host Response and Molecular Dynamics in Periampullary Cancer

Lund University·observational·Posted Oct 30, 2018·Updated Aug 29, 2025

In Brief

An observational study evaluating Gemcitabine for Periampullary Adenocarcinoma and 2 related conditions. Completed, enrolled 201 participants across 1 site.

Detailed Summary

The CHAMP (Chemotherapy, Host response And Molecular dynamics in Periampullary cancer) study is a prospective, single-arm observational study that started Sept 1 2018. Patients diagnosed with pancreatic or other periampullary adenocarcinoma undergoing adjuvant och palliative chemotherapy are invited to participate. The study will examine the tumors' molecular dynamics and how this may change over time and with treatment. Primary endpoint will be overall survival, secondary endpoints will be disease specific survival, time to progression, and quality of life. We estimate that 90 patients will be included in the study per year.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPeriampullary Adenocarcinoma, Periampullary Cancer, Pancreatic Cancer
CountriesSweden
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedOct 30, 2018
Enrollment StartOct 30, 2018
Primary CompletionDec 31, 2024
TodayJul 2, 2026
Enrollment to primary: 6.2 yearsPosted 7.7 years ago

Interventions

Gemcitabinedrug

Adjuvant or palliative chemotherapy according to national guidelines